转自：北京日报客户端 寒冷的冬季是心血管疾病的高发季节。阿司匹林这款常用药也成为很多老年人预防心血管疾病的选择。 阿司匹林的主要适应症是什么？适合长期大量服用吗？是否会带来一些副作用？ 中国医学科学院阜外医院心内科医生刘凯告诉记者，阿司匹林的应用历史很长，最初作为解热镇痛和抗 炎药物应用于临床。后来发现它能够抑制血小板聚集，因而具有良好的预防血栓形成的作用。目前已作 为一种标准治疗药物，被广泛应用于冠心病、脑血管病、外周血管狭窄等各种动脉粥样硬化性疾病的治 疗和预防中。 他表示，针对具体患者，仍需在充分评估的基础上给予个体化的策略，例如调整阿司匹林的应用疗程与 剂量，或必要时考虑其他替代药物（例如氯吡格雷、吲哚布芬等），尽可能减少其出血风险。 梅奥诊所说，对于大多数成年人来说，偶尔服用一两片阿司匹林来缓解头痛、身体疼痛或发烧通常是安 全的。但如果身体健康，没有心脏病或中风病史，每日服用阿司匹林的益处并不明显，甚至可能会产生 严重的副作用和并发症，包括：可能增加出血性中风的风险；增加胃肠道出血风险；导致过敏反应等。 来源：新华社 作者: 彭茜 由于胃刺激是阿司匹林常见的副作用，该药物的正确服用方式也很有讲究。北 ...

剑医见诵 〖亿欧智库 | | 报告背景 | | --- | --- | | ● | 本报告聚焦先进的数据采集技术，确保所获取的销售信息真实、及时且全面，力图从海量数据中提炼出有价值的行业 | | | 趋势与消费洞察，为医药行业的从业者、投资者以及政策制定者提供一份详实可靠的参考依据，助力各方在市场竞争 | | | 中找准定位，优化决策策略。 | | | 数据涵盖范围 药店数据维度 | | | ● 本报告通过监测全国13.5万余家药店，构建了庞大的数据样本库，全面覆 订单量 | | | 盖了不同地区、类型和规模的药店，为分析提供了广泛的代表性。 订单内处方药销量 | | | 订单发生时间 ● 在数据收集过程中,我们成功获取了1400万人次的处方药采购订 | | | 订单所在省份 单信息，这些订单涵盖了各类处方药和中药品种的购买行为，真实反映了 | | | 市场动态和消费者需求。 订单对应的病症 | | | 订单对应病症采购的药品 ● 通过运用先进的数据分析技术,本报告从涵盖10余个分析维度的多 | | | 采购药品对应规格 角度深入剖析数据,包括但不限于销售趋势、地域差异、产品类别、消费 | | | 者行为等， ...

2025 年11月处方药销售全景洞察： 数据驱动・精准破局 亿欧智库 https://www.iyiou.com/research Copyright reserved to EO Intelligence, December 2025 2025 年 1-11 月全国线下药店处方药订单量呈波动上升态势，11 月订单指数达 23.7，增长势头良好。省份分布差异 明显，广东、四川、山东等经济发达、人口密集省份订单占比领先，西藏、青海等西部省份占比极低，反映出区域 药品需求与医疗资源配置的差异。且各省份订单量同比无大幅波动，市场格局相对稳定。 报告数据描述 | | 报告背景 | | | --- | --- | --- | | • | 本报告聚焦先进的数据采集技术，确保所获取的销售信息真实、及时且全面，力图从海量数据中提炼出有价值的行业 趋势与消费洞察，为医药行业的从业者、投资者以及政策制定者提供一份详实可靠的参考依据，助力各方在市场竞争 | | | | 中找准定位，优化决策策略。 | | | | 数据涵盖范围 | 药店数据维度 | | • | 本报告通过监测全国13.5万余家药店，构建了庞大的数据样本库，全面覆 | ...

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Tianfang Pharmaceutical, has received approval for the supplement application of enteric-coated aspirin tablets, which have passed the consistency evaluation for generic drug quality and efficacy [1][3]. Group 1: Drug Approval Information - The drug approved is enteric-coated aspirin tablets, with a specification of 100mg and classified as a chemical drug [1]. - The approval was granted based on the Drug Administration Law of the People's Republic of China and relevant regulations regarding the consistency evaluation of generic drugs [1]. Group 2: Drug Usage and Market Context - Enteric-coated aspirin tablets are primarily used for treating unstable angina, acute myocardial infarction, and preventing recurrent myocardial infarction, among other conditions [2]. - As of the announcement date, the total R&D investment for this drug project is approximately 9.36 million RMB (about 1.3 million USD) [4]. - The domestic annual sales for this drug in public hospitals and primary medical terminals are estimated to be around 2.8 billion RMB (approximately 400 million USD) for 2024, with first-quarter sales for 2025 at about 800 million RMB (approximately 113 million USD) [5]. Group 3: Market Competition - Other companies, including Chenxin Pharmaceutical and Lepu Medical, have also passed or are deemed to have passed the consistency evaluation for this drug, with a total of 20 companies in the domestic market [5]. Group 4: Impact on the Company - The approval of the drug is expected to enhance its market share due to increased support in medical insurance payments and procurement by medical institutions [7].

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the supplemental application of enteric-coated aspirin tablets [1] Group 1 - The approval signifies a regulatory milestone for Tianfang Pharmaceutical, enhancing its product portfolio [1] - Enteric-coated aspirin tablets are expected to meet market demand, potentially increasing the company's revenue [1] - This development reflects the company's commitment to expanding its pharmaceutical offerings in response to healthcare needs [1]

Group 1 - The core point of the article is that China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the supplement application of enteric-coated aspirin tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] - The enteric-coated aspirin tablets are primarily used for the treatment of unstable angina, acute myocardial infarction, prevention of recurrent myocardial infarction, post-arterial vascular surgery or interventional surgery, prevention of transient ischemic attacks, and prevention of cerebral infarction after early symptoms have appeared [1]

Core Viewpoint - The announcement indicates that Tianfang Pharmaceutical, a subsidiary of China Pharmaceutical, has received approval from the National Medical Products Administration for the supplement application of enteric-coated aspirin tablets, which have passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Market Potential - The enteric-coated aspirin tablets are primarily used for the treatment of unstable angina and acute myocardial infarction, with Bayer being the original manufacturer [1] - A total of 20 domestic companies have either passed or are deemed to have passed the consistency evaluation for this drug [1] Group 2: Sales Forecast - The estimated annual sales for this drug in domestic public hospitals and grassroots medical terminals is approximately 2.8 billion yuan for 2024 [1] - The projected sales for the first quarter of 2025 are around 800 million yuan [1]

Core Viewpoint - Shuyou Shen is gaining market attention as an innovative drug development and commercialization company, focusing on clinical value and advancing its pipeline projects through strategic partnerships and external capital infusion [1][2]. Group 1: Company Strategy and Developments - The establishment of the subsidiary Beijietai in Wuxi is aimed at leveraging the favorable business environment and support for biopharmaceutical innovation [1][2]. - Shuyou Shen has received a total of 200 million yuan from the Jin Yi Yuan Li Fund for capital increase and equity transfer, indicating strong external investment interest [1]. - The company is committed to a strategy of innovation-driven development, focusing on differentiated competition and advancing drug commercialization [1][2]. Group 2: R&D Focus and Pipeline - Shuyou Shen is concentrating resources on clinical-stage projects with clear commercialization potential, particularly in areas such as neurological diseases, respiratory and critical care, infectious diseases, and autoimmune diseases [4]. - The company has multiple projects in clinical trials, with STSA-1002 and BDB-001 nearing completion of Phase II trials, and BDB-001 recognized as a breakthrough therapy by the National Medical Products Administration in 2023 [4]. - The company is also exploring the application of artificial intelligence in drug development to enhance efficiency and reduce costs [5][6]. Group 3: Market Position and Product Offerings - Shuyou Shen's main marketed products include innovative biopharmaceuticals such as Su Tai Sheng (injection of mouse nerve growth factor) and Shuyai Qing (compound polyethylene glycol electrolyte solution) [6]. - The company is actively iterating on its existing products, with new formulations launched since 2022 to improve patient compliance and accessibility [6].

Core Insights - The report indicates that the Chinese healthcare service market is expected to exceed 10 trillion RMB in 2024, driven by an aging population and increasing demand for chronic disease management and rehabilitation care [1][5][7] - The integration of technology and healthcare is transforming the industry, with AI models and robotic technologies enhancing diagnostic and treatment efficiency [1][19] Market Overview - The Chinese healthcare service market has grown from approximately 4 trillion RMB in 2015 to about 9 trillion RMB in 2023, with a projected compound annual growth rate (CAGR) of 10-12% [7][8] - By the end of 2024, the total number of healthcare institutions in China is expected to reach 1.092 million, with a notable increase in grassroots medical institutions [9][10] Demographic Changes - The aging population is a significant driver of healthcare demand, with 60 years and older population reaching 310 million (22% of the total population) by 2024 [10][11] - The low birth rate is impacting obstetrics and pediatrics, leading to a decline in resources in these areas, while assisted reproductive technology is gaining traction due to policy support [11][15] Policy and Regulatory Environment - The healthcare reform in 2024 is characterized by stringent drug price controls and anti-corruption measures, which are reshaping the industry towards quality over quantity [16][20] - The implementation of DRG (Diagnosis-Related Group) payment systems and the promotion of the Sanming healthcare reform model are driving hospitals to optimize service structures [22][23] Investment Trends - The A-share healthcare service sector experienced volatility in 2024, with a total of 29 merger and acquisition transactions valued at 6.3 billion RMB, focusing on consumer and serious medical fields [2][24] - The Hong Kong market has become a key exit for domestic healthcare companies, with several firms successfully listing and attracting significant investment [41][42] Technological Integration - The integration of AI and other advanced technologies is revolutionizing healthcare delivery, with AI models achieving high accuracy in clinical applications [19][20] - The development of smart healthcare systems is essential for improving service delivery and efficiency in the face of increasing demand [23][24] Market Challenges and Opportunities - The healthcare service sector is facing challenges from regulatory pressures and market fluctuations, but opportunities exist in specialized medical fields and technological advancements [24][29] - The shift towards value-based care and the emphasis on high-quality services are expected to create new growth avenues for healthcare providers [22][23]

Core Viewpoint - The company has made significant progress in product approvals and innovation, enhancing its market position and revenue potential in the pharmaceutical industry. Group 1: Product Approvals and Sales - In 2025, the company received multiple product approvals, including Mecobalamin tablets and enteric-coated Aspirin tablets, which will enrich its product line in the nervous system category [1] - The sales revenue for Mecobalamin tablets in Chinese public medical institutions was approximately 1.431 billion yuan in 2023, while the sales for enteric-coated Aspirin tablets reached about 3.3 billion yuan [1] Group 2: Research and Development - The company is focusing on R&D in various therapeutic areas, including cardiovascular, analgesics, digestive system, anti-metabolic, nervous system, and narcotic drugs, with over 100 drugs in the development pipeline [2][3] - It has established multiple large R&D platforms and is advancing several first-class innovative drugs, such as OAB-14 for Alzheimer's treatment [2] - The company emphasizes collaboration with academic institutions and has partnerships with over 50 domestic and international research organizations [3] Group 3: Financial Performance - In Q1 2025, the company reported a revenue of 2.43 billion yuan and a net profit of 112 million yuan [4] - For the year 2024, the total revenue was 8.466 billion yuan, reflecting a year-on-year growth of 4.51%, while the net profit was 470 million yuan, slightly declining due to price reductions aimed at market capture [4] - The company plans a high dividend distribution, proposing a payout of 2.5 yuan per 10 shares (including tax) for 2024 [4]